Immatics (IMTX) Set to Release Earnings on Tuesday

Immatics (NASDAQ:IMTX) will likely be posting its Q3 2026 results before the market opens on Tuesday, November 17th. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $12.18 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 20, 2026 at 12:30 PM ET.

Immatics (NASDAQ:IMTX) last announced its earnings results on Tuesday, August 18th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.06). The company had revenue of $10.44 million for the quarter, compared to analyst estimates of $12.42 million. Immatics had a negative return on equity of 47.41% and a negative net margin of 495.71%. On average, analysts expect Immatics to post ($1.99) EPS for the current fiscal year and ($2.01) EPS for the next fiscal year.

Immatics Trading Up 1.1%

Shares of IMTX opened at $6.43 on Tuesday. The stock’s 50-day moving average price is $7.95 and its two-hundred day moving average price is $9.48. Immatics has a 12 month low of $6.09 and a 12 month high of $12.41. The company has a market capitalization of $878.92 million, a PE ratio of -3.46 and a beta of 1.38.

Insiders Place Their Bets

In other news, Director Perceptive Advisors Llc bought 863,060 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The shares were acquired at an average price of $8.69 per share, for a total transaction of $7,499,991.40. Following the completion of the acquisition, the director directly owned 11,246,516 shares in the company, valued at approximately $97,732,224.04. This represents a 8.31% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Analyst Ratings Changes

IMTX has been the subject of several recent research reports. Stifel Nicolaus assumed coverage on Immatics in a research note on Tuesday, October 13th. They issued a “buy” rating and a $15.00 price target for the company. Mizuho set a $21.00 price objective on Immatics in a research note on Thursday, October 29th. Wall Street Zen cut Immatics from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Immatics in a research report on Friday, September 18th. Finally, Jefferies Financial Group set a $17.00 target price on shares of Immatics in a research report on Tuesday, August 25th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Immatics has an average rating of “Moderate Buy” and an average price target of $19.00.

About Immatics

Immatics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Founded in Germany in 2000, the company uses its target-discovery and development platforms to identify cancer-associated targets and create therapies designed to direct the immune system against tumor cells.

Its pipeline includes engineered T-cell receptor (TCR) T-cell therapies, which modify a patient’s T cells to recognize specific tumor targets, as well as TCR bispecific therapies designed to connect T cells with cancer cells.